|
Hematologic Malignancies FY17 A focus on Hodgkin's lymphoma and cutaneous T-cell lymphoma |
09/09/2016 - 9:00am to 10:00am EDT |
|
Hematologic Malignancies FY17 The Past, Present, and Future of Acute Myeloid Leukemia: Understanding the Role of SET and PP2A |
09/16/2016 - 9:00am to 10:00am EDT |
|
Hematologic Malignancies FY17 Emerging Therapies for MLL Rearrangement Leukemia |
09/23/2016 - 9:00am to 10:00am EDT |
|
Hematologic Malignancies FY17 four recent FDA approved drugs for myeloma |
09/30/2016 - 9:00am to 10:00am EDT |
|
Hematologic Malignancies FY17 Expanding the use of TKIs in ALL and CML |
10/07/2016 - 9:00am to 10:00am EDT |
|
Hematologic Malignancies FY 17 Nodular Lymphocyte Predominant HL: Dr. Jekyll or Mr. Hyde |
10/14/2016 - 9:00am to 10:00am EDT |
|
Hematologic Malignancies FY17 history of allogeneic Hematopoietic Cell transplantation |
10/21/2016 - 9:00am to 10:00am EDT |
|
Hematologic Malignancies FY17 MALT Lymphoma of the Ocular Adnexa |
10/28/2016 - 9:00am to 10:00am EDT |
|
Hematologic Malignancies FY17 Unanticipated Cardiomyopathy due to targeted Anticancer Therapy |
11/04/2016 - 9:00am to 10:00am EDT |
|
Hematologic Malignancies FY17 MRD in Multiple Myeloma |
11/11/2016 - 9:00am to 10:00am EST |
Facebook
X
LinkedIn
Forward